江苏康宁杰瑞生物制药有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Alphamab Oncology Presented Clinical Data of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at AACR 2021 2021-04-13 08:15
Alphamab Oncology Reports Full Year 2020 Financial Results and Business Highlights 2021-03-23 23:08
Alphamab Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S. 2021-03-09 20:00
Alphamab Oncology announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KN046 for the treatment of thymic epithelial tumor 2020-09-03 23:46
Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody 2020-06-10 08:40
Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer 2020-06-09 10:10
Alphamab Oncology, Simcere and 3D Medicines Announce Partnership to Develop and Commercialize Subcutaneous Injectable anti-PD-L1 Antibody for Oncology Indications in Mainland China 2020-03-30 19:00
Alphamab Oncology Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance(R) (palbociclib) 2020-03-27 19:00
Alphamab Oncology Announces Completion of US$60 Million Series B Financing 2019-05-28 19:02
Alphamab Oncology is Invited to Present at the 37th Annual J.P. Morgan Healthcare Conference 2019-01-04 17:02
Alphamab Oncology Completes Series-A Round Financing - Further Strengthening Its Global Innovative Biologics Platforms 2018-11-17 00:12
KN035, a Global Leading Subcutaneously-administered PD-L1 Antibody, Starts Late-stage Clinical Development 2018-10-23 19:03
Alphamab Oncology's HER2 bispecific antibody KN026 gained US IND approval; phase I clinical trial started in China 2018-10-16 18:18
Alphamab Oncology's first-in-class PD-L1 - CTLA-4 bispecific antibody enters clinical trial 2018-10-10 18:36
1 2 3 4